UpdatesPlus Substance Use Disorder - breaking information on smoking cessation, reduced harm tobacco and treatment of drug abuse

We are pleased to announce the release of our most recent issue of UpdatesPlus-Substance Use Disorder.  This issue covers smoking cessation, reduced harm tobacco products and treatments of illicit substance abuse.  

For access instructions please contact fiona.watts@leaddiscovery.co.uk

The issue includes

• New data on Champix/Chantix retreatment and the potential for an sNDA, revenue growth and possible fueling of Pfizer's continued direct to consumer strategy.  We also include information on the FDA AdCom meeting announced for Oct 16 to discuss neuropsychiatric risk of Chantix
  
• A look into both the The Tobacco Products Scientific Advisory Committee meeting and the FDA's proposal on regulation of smokeless tobacco products including e-cigarettes
• A full update on e-cigarette/reduced harm products development including a detailed look into PMI's evolving scientific approach
• Activity around alcohol abuse including recommendation of Selincro by NICE and new therapeutic targets including adrenoceptor receptor blockade; GALR3 antagonists
  
• The trials and tribulations of Orexo's launch of Zubsolv (opiate maintenance therapy), apparently negatively affected by Publicis Touchpoint's commercialization efforts; a new partnership with inVentiv Health; generic attack from Actavis; and positive clinical results demonstrating utility as an induction therapy
• PDE4 inhibition as a novel approach to opiate addiction
  
• Significant activity around new naloxone preparations for opiate overdose reversal
• New proof of concept supporting development of mGlu2 PAMs; D3 antagonists and TAAR1agonists as novel approaches to cocaine addiction
  

The issue is made up of 64 slides analyzing recent information released in the area of Substance Use Disorder including commercial activity, up to date pipeline and clinical timeline charts, clinical data and proof of concept papers describing new targets


*UpdatesPlus was set up nearly 15 years ago by R&D experts and has since developed into a well respected intelligence tool spanning the immunology and dermatology spectrum. We identify breaking research, clinical trial activity, drug development news and commercial events across multiple therapy areas including psoriasis, IBD, RA and many more.  What makes us really unique is our expert analysis of this information.  This analysis is packaged in monthly reports and ad hoc alerts.